In a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According to ...

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ...

With extensive industry leadership experience, Mr. Oliverio is poised to drive Actineer’s global expansion in Actinium-225 (Ac-225) production. Mr. Oliverio joins Actineer with over three ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...